CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - TSX:CPH - CA17253X1050 - Common Stock
13.15 CAD
-0.14 (-1.05%)
Overall CPH gets a fundamental rating of 5 out of 10. We evaluated CPH against 32 industry peers in the Pharmaceuticals industry. CPH scores excellent on profitability, but there are some minor concerns on its financial health. CPH is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
CPH had positive earnings in the past year.
CPH had a positive operating cash flow in the past year.
In the past 5 years CPH has always been profitable.
In the past 5 years CPH always reported a positive cash flow from operatings.
1.2 Ratios
CPH has a better Return On Assets (7.98%) than 87.10% of its industry peers.
The Return On Equity of CPH (11.13%) is better than 87.10% of its industry peers.
CPH's Return On Invested Capital of 5.20% is fine compared to the rest of the industry. CPH outperforms 77.42% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 7.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.98% | ||
| ROE | 11.13% | ||
| ROIC | 5.2% |
ROA(3y)22.24%
ROA(5y)18.4%
ROE(3y)26.01%
ROE(5y)22.38%
ROIC(3y)8.41%
ROIC(5y)14.91%
1.3 Margins
CPH's Profit Margin of 25.49% is amongst the best of the industry. CPH outperforms 96.77% of its industry peers.
CPH's Profit Margin has improved in the last couple of years.
CPH has a better Operating Margin (20.32%) than 87.10% of its industry peers.
In the last couple of years the Operating Margin of CPH has declined.
The Gross Margin of CPH (73.79%) is better than 93.55% of its industry peers.
In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.32% | ||
| PM (TTM) | 25.49% | ||
| GM | 73.79% |
OM growth 3Y-26.61%
OM growth 5Y-14.41%
PM growth 3Y0.56%
PM growth 5Y20.04%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPH is still creating some value.
CPH has more shares outstanding than it did 1 year ago.
CPH has less shares outstanding than it did 5 years ago.
CPH has a worse debt/assets ratio than last year.
2.2 Solvency
CPH has an Altman-Z score of 4.71. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
CPH's Altman-Z score of 4.71 is amongst the best of the industry. CPH outperforms 93.55% of its industry peers.
CPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
CPH has a Debt to Equity ratio (0.23) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.71 |
ROIC/WACC0.66
WACC7.91%
2.3 Liquidity
CPH has a Current Ratio of 1.72. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.72, CPH perfoms like the industry average, outperforming 48.39% of the companies in the same industry.
CPH has a Quick Ratio of 1.41. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
CPH has a Quick ratio of 1.41. This is comparable to the rest of the industry: CPH outperforms 54.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
CPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 114.76%.
CPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.25% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%83.33%
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
3.2 Future
The Earnings Per Share is expected to grow by 13.16% on average over the next years. This is quite good.
Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 21.67% on average per year.
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.55, which indicates a rather expensive current valuation of CPH.
Compared to the rest of the industry, the Price/Earnings ratio of CPH indicates a rather cheap valuation: CPH is cheaper than 83.87% of the companies listed in the same industry.
CPH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.89.
A Price/Forward Earnings ratio of 14.29 indicates a correct valuation of CPH.
77.42% of the companies in the same industry are more expensive than CPH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, CPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.55 | ||
| Fwd PE | 14.29 |
4.2 Price Multiples
CPH's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 15.02 |
4.3 Compensation for Growth
CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has a very decent profitability rating, which may justify a higher PE ratio.
CPH's earnings are expected to grow with 13.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.54
PEG (5Y)1.58
EPS Next 2Y19.46%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
CPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CPH (11/14/2025, 7:00:00 PM)
13.15
-0.14 (-1.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap332.96M
Revenue(TTM)47.59M
Net Income(TTM)12.13M
Analysts77.5
Price Target18.26 (38.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.48%
Min EPS beat(2)-7.18%
Max EPS beat(2)36.14%
EPS beat(4)1
Avg EPS beat(4)-25.25%
Min EPS beat(4)-92.76%
Max EPS beat(4)36.14%
EPS beat(8)5
Avg EPS beat(8)61.68%
EPS beat(12)9
Avg EPS beat(12)108.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-0.23%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)2.48%
Revenue beat(8)3
Avg Revenue beat(8)6.68%
Revenue beat(12)3
Avg Revenue beat(12)0.57%
Revenue beat(16)3
Avg Revenue beat(16)-2.32%
PT rev (1m)2.17%
PT rev (3m)13.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-31.15%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)4.34%
Revenue NY rev (3m)1.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.55 | ||
| Fwd PE | 14.29 | ||
| P/S | 4.99 | ||
| P/FCF | N/A | ||
| P/OCF | 11.13 | ||
| P/B | 2.18 | ||
| P/tB | 13.97 | ||
| EV/EBITDA | 15.02 |
EPS(TTM)0.64
EY4.87%
EPS(NY)0.92
Fwd EY7%
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)1.18
OCFY8.99%
SpS2.64
BVpS6.04
TBVpS0.94
PEG (NY)0.54
PEG (5Y)1.58
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.98% | ||
| ROE | 11.13% | ||
| ROCE | 7.22% | ||
| ROIC | 5.2% | ||
| ROICexc | 5.68% | ||
| ROICexgc | 22.71% | ||
| OM | 20.32% | ||
| PM (TTM) | 25.49% | ||
| GM | 73.79% | ||
| FCFM | N/A |
ROA(3y)22.24%
ROA(5y)18.4%
ROE(3y)26.01%
ROE(5y)22.38%
ROIC(3y)8.41%
ROIC(5y)14.91%
ROICexc(3y)14.82%
ROICexc(5y)25.77%
ROICexgc(3y)32.33%
ROICexgc(5y)N/A
ROCE(3y)11.68%
ROCE(5y)20.71%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.06%
ROICexc growth 5Y-33.64%
OM growth 3Y-26.61%
OM growth 5Y-14.41%
PM growth 3Y0.56%
PM growth 5Y20.04%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.49 | ||
| Cap/Depr | 1131.26% | ||
| Cap/Sales | 168.05% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 127.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z | 4.71 |
F-Score5
WACC7.91%
ROIC/WACC0.66
Cap/Depr(3y)669.84%
Cap/Depr(5y)414.47%
Cap/Sales(3y)80.28%
Cap/Sales(5y)48.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%83.33%
EPS Next Y38.33%
EPS Next 2Y19.46%
EPS Next 3Y13.16%
EPS Next 5YN/A
Revenue 1Y (TTM)114.76%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%152.28%
Revenue Next Year55.59%
Revenue Next 2Y30.55%
Revenue Next 3Y21.67%
Revenue Next 5YN/A
EBIT growth 1Y-12.36%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.35%
EBIT Next Year136.87%
EBIT Next 3Y37.76%
EBIT Next 5YN/A
FCF growth 1Y-555.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.92%
OCF growth 3Y13.14%
OCF growth 5Y20.32%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
Can you provide the ChartMill fundamental rating for CIPHER PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to CPH.CA.
What is the valuation status of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
How profitable is CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 4 / 10.